What is new in HIV infection?
Human immunodeficiency virus (HIV) prevention and treatment updates include screening recommendations, fourth-generation testing, preexposure prophylaxis, and a paradigm shift; treatment is prevention. The U.S. Preventive Services Task Force recommends routine HIV screening in persons 15 to 65 years of age, regardless of risk. Fourth-generation testing is replacing the Western blot and can identify those with acute HIV infection. The U.S. Food and Drug Administration approved the OraQuick In-Home HIV Test; however, there are concerns about reduced sensitivity, possible misinterpretation of results, potential for less effective counseling, and possible cost barriers. Preexposure prophylaxis (effective in select high-risk adult populations) is the combination of safer sex practices and continuous primary care prevention services, plus combination antiretroviral therapy. Concerns for preexposure prophylaxis include the necessity of strict medication adherence, limited use among high-risk populations, and community misconceptions of appropriate use. Evidence supports combination antiretroviral therapy as prevention for acute HIV infection, thus lowering community viral loads. Evidence has increased supporting combination antiretroviral therapy for treatment at any CD4 cell count. Resistance testing should guide therapy in all patients on entry into care. Within two weeks of diagnosis of most opportunistic infections, combination antiretroviral therapy should be started; patients with tuberculosis and cryptococcal meningitis require special considerations.
Florida State University College of Medicine, Orlando, FL, USA.
Kevin
K
Sherin
Florida Department of Health, Orlando, FL, USA.
Benjamin G
BG
Klekamp
University of South Florida, Tampa, FL, USA.
Jeffery
J
Beal
Morehouse School of Medicine, Atlanta, GA, USA.
Nicolle
N
Martin
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015483:HIV Antibodies / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000175:diagnosis* / Q000517:prevention & control; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008403:Mass Screening / Q000379:methods*; D055118:Medication Adherence; D019562:Viral Load / Q000187:drug effects
D019380:Anti-HIV Agents; D015483:HIV Antibodies; D015488:HIV Antigens